93 | Bexobrutideg (Nx?5948), a Novel Btk Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/refractory Cll: Updated Findings from Ongoing Phase 1a Study
No Thumbnail Available
All Authors
Danilov,A.
Omer,Z.
Forconi,F.
Shah,N. N.
Collins,G. P.
Ma,S.
Robertson,J.
Alencar,A.
Brander,D.
Byrd,J. C.
LTHT Author
Munir, Talha
LTHT Department
Oncology
Haematology
Haematology
Non Medic
Publication Date
2025
Item Type
Article
Language
Subject
Subject Headings
Abstract
Journal
Hematological oncology